AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The ...

In the latest trading session, Astrazeneca (AZN) closed at $166.68, marking a +2.87% move from the previous day. This move outpaced the S&P 500's daily gain of 0.33%. Elsewhere, the Dow saw an upswing ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

AstraZeneca stock edged lower despite the US FDA granting accelerated approval for the company’s new breast cancer pill ...

AstraZeneca stock is trading in the mid-$160 range as a new €2.55 billion eurobond offering and consensus targets above $200 highlight how debt funding and analyst expectations intersect with the ...

I'm initiating coverage on AstraZeneca (AZN) and setting it at a "Strong Buy" rating. The reason why is because the company was able to report massive growth in revenue in Q1 of 2026. During this ...

AstraZeneca stock toppled late Friday after the company's experimental breast cancer treatment failed to pass muster.

AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.